Innovative ‘Smart’ Cancer Drug Targets Tumors Without Harming Healthy Cells
A groundbreaking advancement in cancer treatment has arrived with the development of a new “smart” cancer drug that activates only within cancer cells. This innovative drug, named RK-251, has the potential to replace traditional chemotherapy, which often inadvertently damages healthy cells and leads to several adverse side effects.
Cancer therapies have long struggled with the challenge of targeting tumors without affecting surrounding healthy tissue. The emerging need for targeted treatments has prompted scientists to explore options that remain inactive during transit through the body, becoming active specifically at tumor sites. A collaborative effort between researchers from the Institute of Advanced Study in Science and Technology (IASST) and the Indian Institute of Technology-Guwahati has made significant strides toward realizing this concept.
Led by Dr. Asis Bala from IASST and Dr. K.P. Bhabak from IIT-Guwahati, the team has successfully developed RK-251, a drug that activates primarily within cancer cells while sparing healthy cells from harm. This unique approach targets the high levels of reactive oxygen species (ROS) that are commonly found in cancerous tissues.
Mechanism of Action
When RK-251 enters a cancer cell, the elevated ROS levels trigger the drug’s activation. This process releases a potent anticancer compound known as “NBDHEX,” which effectively blocks key survival proteins that many cancer cells rely on to endure treatment. Preliminary studies have demonstrated that RK-251 exhibits strong efficacy against aggressive triple-negative breast cancer cells with significantly reduced effects on healthy cells.
Preclinical Success
Further tests conducted using zebrafish embryos revealed no visible toxicity signs from RK-251, indicating a potential safety profile for continued investigation. The drug displayed desired fluorescence in the presence of ROS, which further supports its targeted action within cancer cells. These preclinical findings pave the way for future studies aimed at validating the efficacy and safety of RK-251 for potential use in human patients.
While RK-251 shows great promise, additional research is needed to confirm these results before this groundbreaking technology can be tested in clinical settings. The findings have been published in the ACS Journal of Medicinal Chemistry, solidifying their contributions to cancer research.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
